Drug
Avp 786
Avp 786: highest development phase Phase 2, developed by Otsuka. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) NCT02153502 | Phase 2 | Depressive Disorder, Treatment-Resistant |
| AVP-786 NCT02174835 | Phase 1 | Healthy |
Latest
No recent events.
Follow Avp 786 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.